TransMedics Group Inc vs Tencent Music Entertainment Group - ADR — how do they compare? TransMedics Group Inc trades at $77.87 (market cap $2.74B), while Tencent Music Entertainment Group - ADR trades at $8.38 (market cap $12.83B). The key difference: Tencent Music Entertainment Group - ADR is far larger — about 4.7× TransMedics Group Inc's market cap, and Tencent Music Entertainment Group - ADR pays a 3.02% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold TransMedics Group Inc for 24 Days and Tencent Music Entertainment Group - ADR for 67 Days on average.
| TMDX | TME | |
|---|---|---|
Market Cap | $2.74B | $12.83B |
Volume | 949,331 | 3,618,478 |
Sector | Health | Media |
52-Week High | $150.42 | $23.71 |
52-Week Low | $61.99 | $7.74 |
Typical Hold Time | 24 Days | 67 Days |
Enterprise Value | $3.13B | $10.77B |
Dividend Yield | — | 3.02% |
Signals from Pluang's Aura AI — not financial advice
TMDX trades at $79.00, down 2.55% amid bearish technical signals. The stock shows strong profitability with 22.69% net margin and 36.28% ROE, though recent earnings misses and margin compression from 2025 to 2026 raise concerns. Analyst consensus remains bullish with a $99.75 price target, but multiple legal investigations into fiduciary duties create uncertainty. Revenue growth continues with 2026 guidance at $668M.
The stock presents a growth opportunity with analyst upside potential, but faces near-term headwinds from earnings volatility and legal scrutiny. Execution on 2026 guidance and resolution of governance concerns will be critical for sustained momentum. Current valuation at 20.47 P/E appears reasonable given growth prospects if operational targets are met.
Tencent Music Entertainment (TME) trades at $7.96, down 0.38% on the day, with a bearish technical signal despite strong fundamentals. The company reported robust revenue growth to $32.9B in 2025 and net income of $11.06B, with improving profit margins. Recent developments include a $1B notes offering and a $400M share repurchase program, reflecting financial discipline. Analyst consensus is mixed with 41.7% buy ratings but a $12.50 price target suggesting significant upside from current levels.
TME presents a compelling value opportunity with attractive valuation multiples (P/E 9.33, P/S 2.46) and strong profitability metrics. However, investors face risks from intense competition, regulatory oversight in China, and recent earnings misses. The stock's current discount to analyst targets offers potential upside, but requires monitoring of user growth trends and competitive pressures from short-form video platforms.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →TME is the largest online music service provider in China. It was founded in 2016 with the business combination of QQ Music (founded in 2005), Kuwo Music (founded in 2005) and Kugou Music (founded in 2004) streaming platforms. Tencent is the largest shareholder of TME with over 50% shares and over 90% voting rights held. TME also provides social entertainment services, including music live audio/video broadcasts and online concert services through the three platforms mentioned above, and online karaoke through an independent platform WeSing.
Read more on TME →